Jun. 21 at 11:38 PM
$ALMS Alumis resumed with an Overweight at Morgan Stanley
TheFly Jun 01, 2025, 07:30 PM
Morgan Stanley resumed coverage of Alumis (ALMS) with an Overweight rating and
$23 price target and updated its model for the merger and Q1 earnings. The Phase 3 data from Alumis’ lead pipeline program ESK-001 in psoriasis in Q1 of 2026 represents the next key catalyst for the shares, the analyst tells investors in a research note. Morgan believes the company’s pipeline is on track.
Alumis resumed with a Buy at Guggenheim
TheFly Jun 10, 2025, 08:05 AM
Guggenheim analyst Yatin Suneja resumed coverage of Alumis (ALMS) with a Buy rating and
$18 price target with the merger with Acelyrin completed. The firm, which highlights the two recent milestones of the announcement of the 52-week Phase 2 OLE data for ESK-001 in psoriasis in March and the completion of Phase 3 ONWARD trials patient enrollment, updated its model to reflect the new share count and cash position post-Acelyrin merger.
$EDIT $IDRX.X
$RXRX
